Hadasit Ltd. to Assign to Immuron an Oral Immune Modulation Technology Developed at Hadassah Medical Center

Published: Apr 20, 2009

NEW YORK & MELBOURNE, Australia & JERUSALEM--(BUSINESS WIRE)--Hadasit, the technology transfer company of the Hadassah Medical Organization, and Immuron, a biopharmaceutical company, announced today an agreement whereby Immuron will assign from Hadasit a novel oral immune modulation technology that was developed by Hadassah physicians and scientists. This marks Hadasit’s latest successful licensing of early stage intellectual property to a partner.

Back to news